GOODWILL(SH:688246) Xin Lang Cai Jing·2025-11-12 01:39Summary of Key Points Core Viewpoint - 嘉和美康 has experienced a significant decline in revenue and net profit for the first nine months of 2025, indicating potential challenges in its business operations and market position [2]. Group 1: Financial Performance - For the period from January to September 2025, 嘉和美康 reported operating revenue of 330 million yuan, a year-on-year decrease of 30.67% [2]. - The company recorded a net profit attributable to shareholders of -174 million yuan, representing a year-on-year decrease of 320.68% [2]. Group 2: Shareholder and Market Activity - As of September 30, 2025, 嘉和美康 had 7,592 shareholders, an increase of 1.84% compared to the previous period [2]. - The average number of circulating shares per shareholder was 18,122, a decrease of 1.80% from the previous period [2]. - On November 11, 嘉和美康's stock price fell by 0.59%, with a trading volume of 60.01 million yuan [1]. Group 3: Financing and Margin Trading - On November 11, 嘉和美康 had a financing buy-in amount of 8.86 million yuan and a financing repayment of 9.05 million yuan, resulting in a net financing buy of -185,800 yuan [1]. - The total margin trading balance for 嘉和美康 was 187 million yuan, accounting for 5.42% of its market capitalization, which is above the 80th percentile of the past year [1]. - The company had no short selling activity on November 11, with a short selling balance of 0 [1]. Group 4: Business Overview - 嘉和美康 (Beijing Jiahe Meikang Technology Co., Ltd.) was established on March 3, 2006, and went public on December 14, 2021 [1]. - The company's main business involves the research and industrialization of medical information software, with revenue composition as follows: software development and technical services (42.39%), self-developed software sales (37.64%), purchased software and hardware sales (19.86%), and other service sales (0.11%) [1].